The UBP1 antibody targets ubiquitin-specific protease 1 (UBP1), a member of the deubiquitinating enzyme (DUB) family that regulates protein stability by removing ubiquitin chains. UBP1. also known as USP1. plays critical roles in DNA repair, cell cycle control, and stem cell maintenance. It interacts with proteins like FANCI and PCNA, modulating the Fanconi anemia pathway and translesion DNA synthesis. Dysregulation of UBP1 is linked to cancer progression, chemotherapy resistance, and genetic disorders.
UBP1 antibodies are essential tools for studying its expression, localization, and function. They are typically produced in hosts like rabbits or mice using immunogenic peptides or recombinant protein fragments. These antibodies are validated through techniques such as Western blotting, immunoprecipitation, and immunofluorescence to ensure specificity. Researchers use them to investigate UBP1's role in maintaining genomic stability, its inactivation via autocleavage during the cell cycle, and its potential as a therapeutic target. Commercial UBP1 antibodies often cite applications in cancer research, particularly in contexts involving cisplatin sensitivity, stem cell differentiation, and DNA damage response pathways. Proper controls, including knockout cell lines, are recommended to confirm antibody reliability.